H1 2026 sales grew 44% at constant exchange rates, led by strong U.S. probe sales and rapid international expansion of CellTolerance, which surged 145%. Profitability is targeted by year-end 2027, supported by a strengthened balance sheet and robust sales pipeline.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.